Hanshiyi Formula, a medicine for Sars-CoV2 infection in China, reduced the proportion of mild and moderate COVID-19 patients turning to severe status: A cohort study
Jiaxing Tian, Shiyan Yan, Han Wang, Ying Zhang, Yujiao Zheng, Haoran Wu, Xiuyang Li, Zezheng Gao, Yanke Ai, Xiaowen Gou, Lei Zhang, Liyun He, Fengmei Lian, Baoyan Liu, Xiaolin Tong
Topics & Concepts
MedicinePropensity score matchingInternal medicineConfidence intervalCoronavirus disease 2019 (COVID-19)Univariate analysisDiseaseCohortRetrospective cohort studyCohort studyMedical prescriptionMultivariate analysisInfectious disease (medical specialty)PharmacologyCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19SARS-CoV-2 and COVID-19 Research